SCHEMBL3975016

SCHEMBL3975016

CC(=O)OCCc1ccc(C(=O)C(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
KDM4E B2RXH2 1/20 0.40
DBH P09172 1/20 0.40
GAA P10253 1/20 0.40
RECQL P46063 1/20 0.40
TYR P14679 1/20 0.39
ALDH1A1 P00352 3/20 0.38
LMNA P02545 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30334133 0.88 NPC1 (0.44) NPC1RAB9AMAPTSMN1; SMN2CYP4F2
SCHEMBL86418 0.82 KMT2A (0.55) NPC1RAB9AMAPTSMN1; SMN2ESR1
SCHEMBL8673483 0.82 L3MBTL1 (0.50) RAB9AMAPTSMN1; SMN2GAAALDH1A1
SCHEMBL3685675 0.82 KDM4E (0.50) SMN1; SMN2CYP4F2CYP4A11KDM4EDBH
SCHEMBL10053298 0.79 L3MBTL1 (0.44) NPC1RAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL20630223 0.79 KMT2A (0.55) RAB9AMAPTSMN1; SMN2CYP4F2CYP4A11
SCHEMBL17921593 0.78 L3MBTL1 (0.46) RAB9AMAPTKDM4EGAAALDH1A1
SCHEMBL18417676 0.78 L3MBTL1 (0.46) RAB9AMAPTKDM4EGAAALDH1A1
SCHEMBL19291179 0.78 ACACB (0.41) NPC1RAB9AMAPTSMN1; SMN2TYR
SCHEMBL2387797 0.77 LMNA (0.52) NPC1RAB9AMAPTSMN1; SMN2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129039-A1 NOVEL PROCESS FOR THE PREPARATION OF BILASTINE AND INTERMEDIATES THEREOF BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) 2025-04-24 US disclosed
WO-2023037184-A2 NOVEL PROCESS FOR THE PREPARATION OF BILASTINE AND INTERMEDIATES THEREOF BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) 2023-03-16 WO disclosed
US-8367743-B2 Adhesion promoting photoinitiators for UV cured coatings over metal surfaces BASF SE (DE) 2013-02-05 US disclosed
US-20090104464-A1 Adhesion promoting photoinitiators for UV cured coatings over metal surfaces IGM GROUP B.V. (NL) 2009-04-23 US disclosed
WO-2009050116-A2 ADHESION PROMOTING PHOTOINITIATORS FOR UV CURED COATINGS OVER METAL SURFACES BASF SE (DE) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090104464-A1 Adhesion promoting photoinitiators for UV cured coatings over metal surfaces CDH1, PCNA, VCAM1 NPC1 4847/4885RAB9A 2862/4885MAPT 361/4885
US-20250129039-A1 NOVEL PROCESS FOR THE PREPARATION OF BILASTINE AND INTERMEDIATES THEREOF CYP4B1, CYP3A4, CYP7A1 NPC1 2275/4885RAB9A 1947/4885MAPT 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.